[go: up one dir, main page]

PL3526321T3 - Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami - Google Patents

Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami

Info

Publication number
PL3526321T3
PL3526321T3 PL17859455.2T PL17859455T PL3526321T3 PL 3526321 T3 PL3526321 T3 PL 3526321T3 PL 17859455 T PL17859455 T PL 17859455T PL 3526321 T3 PL3526321 T3 PL 3526321T3
Authority
PL
Poland
Prior art keywords
associated virus
recombinant adeno
virus yield
tonicifying agents
enhance recombinant
Prior art date
Application number
PL17859455.2T
Other languages
English (en)
Inventor
Ying JING
Jan PANTELI
Original Assignee
Ultragenyx Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61906054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3526321(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ultragenyx Pharmaceutical Inc. filed Critical Ultragenyx Pharmaceutical Inc.
Publication of PL3526321T3 publication Critical patent/PL3526321T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17859455.2T 2016-10-14 2017-10-13 Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami PL3526321T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408420P 2016-10-14 2016-10-14
PCT/US2017/056588 WO2018071817A1 (en) 2016-10-14 2017-10-13 Use of tonicifying agents to enhance recombinant adeno-associated virus yield

Publications (1)

Publication Number Publication Date
PL3526321T3 true PL3526321T3 (pl) 2025-04-28

Family

ID=61906054

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17859455.2T PL3526321T3 (pl) 2016-10-14 2017-10-13 Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami

Country Status (5)

Country Link
US (1) US11795473B2 (pl)
EP (1) EP3526321B1 (pl)
ES (1) ES3012649T3 (pl)
PL (1) PL3526321T3 (pl)
WO (1) WO2018071817A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018288B2 (en) 2019-04-12 2024-06-25 Ultragenyx Pharmaceutical Inc. Engineered producer cell lines and methods of making and using the same
US10801042B1 (en) * 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
EP4490278A1 (en) 2022-03-07 2025-01-15 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
EP0796339A1 (en) 1994-12-06 1997-09-24 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
IT1297074B1 (it) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
ES2317709T3 (es) 1998-09-04 2009-04-16 Targeted Genetics Corporation Metodos para generar preparaciones libres de auxiliares de titulo alto de vectores de aav recombinantes liberados.
EP1124976A1 (en) 1998-10-27 2001-08-22 Crucell Holland B.V. Improved aav vector production
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US7195394B2 (en) 2004-07-19 2007-03-27 Vijay Singh Method for resonant wave mixing in closed containers
US8980247B2 (en) 2004-10-21 2015-03-17 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells
WO2007046703A2 (en) 2005-10-20 2007-04-26 Amsterdam Molecular Therapeutics B.V. Improved aav vectors produced in insect cells
US8512981B2 (en) 2006-06-21 2013-08-20 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
GB0706638D0 (en) 2007-04-04 2007-05-16 Mbda Uk Ltd A high-dielectric material
US8580755B2 (en) 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
EP2346996A1 (en) 2008-11-07 2011-07-27 Intelligentnano Inc. Transfection with magnetic nanoparticles and ultrasound
CN102803478B (zh) 2009-06-16 2016-04-27 建新公司 用于纯化重组aav载体的改进方法
US9879229B2 (en) * 2011-03-14 2018-01-30 National Research Council Of Canada Method of viral production in cells
WO2013096955A1 (en) 2011-12-23 2013-06-27 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
BR122020002822B1 (pt) 2013-01-08 2023-04-18 Genzyme Corporation Método para cultivar um vetor de hsv-1 d27.1

Also Published As

Publication number Publication date
US11795473B2 (en) 2023-10-24
EP3526321A4 (en) 2020-05-13
WO2018071817A1 (en) 2018-04-19
EP3526321B1 (en) 2024-11-27
ES3012649T3 (en) 2025-04-09
US20210277416A1 (en) 2021-09-09
EP3526321A1 (en) 2019-08-21
EP3526321C0 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
IL262353A (en) Methods for increasing the potency of a baculovirus system produced using a recombinant adeno-associated virus
ZA201905485B (en) Adeno-associated virus variant capsids and methods of use thereof
ZA201900278B (en) Variant adeno-associated viruses and methods of using
IL266264A (en) Adeno-associated virus formulations
LT3442602T (lt) Mikrodistrofino adeno-asocijuoto viruso vektoriaus pateikimas raumenų distrofijos gydymui
HUE057795T2 (hu) Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
KR102268473B9 (ko) 엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
DK3108000T3 (da) Adeno-associeret virusvektor
EP3373978A4 (en) AGGREGATION OF MICROPARTICLES FOR THERAPY
EP3313413C0 (en) THIOL AND DISULFIDE CONTAINING AGENTS FOR INCREASING LIPID SECRETION OF MEIBOMIUS GLANDS
EP3134113A4 (en) Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
EP3463444C0 (en) ENHANCED IMMUNOGENICITY OF HPV L2 PEPTIDES
DK3113795T3 (da) Rekombinante virale isfahan-vektorer
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
IL295361A (en) Efficient selectivity of recombinant proteins
PL3526321T3 (pl) Zastosowanie środków regulujących ciśnienie osmotyczne w celu zwiększenia wydajności rekombinacyjnego wirusa związanego z adenowirusami
PT3063287T (pt) Utilização de monensina para regular a glicosilação das proteínas recombinantes
EP3484493A4 (en) USE OF GLUCOCORTICOID ANALOGS TO INCREASE THE PERFORMANCE OF RECOMBINANT ADENO-ASSOCIATED VIRUSES
EP3329922A4 (en) GLP-1 secretagogue
GB201504211D0 (en) Use of peptides